|
1
|
Goletz S, Cao Y, Danielcyk A, Ravn P,
Schoeber U and Karsten U: Thomsen-Friedenreich antigen: the
‘hidden’ tumour antigen. Adv Exp Med Biol. 535:147–162. 2003.
|
|
2
|
Cao Y, Merling A, Karsten U and
Schwartz-Albiez R: Expression of Thomsen-Friedenreich-related
carbohydrate antigens on human leukemia cells. Leucocyte Typing
VII. Mason D, et al: Oxford University Press; Oxford: pp. 204–205.
2002
|
|
3
|
Cao Y, Stosiek P, Springer GF and Karsten
U: Thomsen-Friedenreich-related carbohydrate antigens in normal
adult human tissues: a systematic and comparative study. Histochem
Cell Biol. 106:197–207. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Springer GF: T and Tn, general carcinoma
autoantigens. Science. 224:1198–1206. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Springer GF: Immunoreactive T and Tn
epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol
Med. 75:594–602. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aller CT, Kucuk O, Springer GF and
Gilman-Sachs A: Flow cytometric analysis of T and Tn epitopes on
chronic lymphocytic leukemia cells. Am J Hematol. 52:29–38. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaspers GJ, Veerman AJ, Van Wering ER, et
al: Prognostic significance of peanut agglutinin binding in
childhood acute lymphoblastic leukemia. Leukemia. 10:675–681.
1996.PubMed/NCBI
|
|
8
|
Veerman AJ, Hogeman PH, Huismans DR, Van
Zantwijk CH and Bezemer PD: Peanut agglutinin, a marker for T-cell
acute lymphoblastic leukemia with a good prognosis. Cancer Res.
45:1890–1893. 1985.PubMed/NCBI
|
|
9
|
Lin WM, Karsten U, Goletz S, Cheng RC and
Cao Y: Expression of CD176 (Thomsen-Friedenreich antigen) on lung,
breast and liver cancer-initiating cells. Int J Exp Pathol.
92:97–105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cao Y, Karsten UR, Liebrich W, Haensch W,
Springer GF and Schlag PM: Expression of
Thomsen-Friedenreich-related antigens in primary and metastatic
colorectal carcinomas. A reevaluation. Cancer. 76:1700–1708. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Glinsky VV, Glinsky GV, Rittenhouse-Olson
K, et al: The role of Thomsen-Friedenreich antigen in adhesion of
human breast and prostate cancer cells to the endothelium. Cancer
Res. 61:4851–4857. 2001.PubMed/NCBI
|
|
12
|
Heimburg J, Yan J, Morey S, et al:
Inhibition of spontaneous breast cancer metastasis by
anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11.
Neoplasia. 8:939–948. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao Y, Merling A, Karsten U, et al:
Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176
(Thomsen-Friedenreich antigen) on malignant human hematopoietic
cells. Int J Cancer. 123:89–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
MacLean GD, Bowen-Yacyshyn MB, Samuel J,
et al: Active immunization of human ovarian cancer patients against
a common carcinoma (Thomsen-Friedenreich) determinant using a
synthetic carbohydrate antigen. J Immunother. 11:292–305. 1992.
View Article : Google Scholar
|
|
15
|
Slovin SF, Ragupathi G, Musselli C, et al:
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer
vaccine: clinical trial results with TF cluster (c)-KLH plus QS21
conjugate vaccine in patients with biochemically relapsed prostate
cancer. Cancer Immunol Immunother. 54:694–702. 2005. View Article : Google Scholar
|
|
16
|
Dougan M and Dranoff G: Immune therapy for
cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar
|
|
17
|
Yi B, Zhang M, Schwartz-Albiez R and Cao
Y: Mechanisms of the apoptosis induced by CD176 antibody in human
leukemic cells. Int J Oncol. 38:1565–1573. 2011.PubMed/NCBI
|
|
18
|
Shigeoka H, Karsten U, Okuno K and
Yasutomi M: Inhibition of liver metastases from
neuraminidase-treated colon 26 cells by an
anti-Thomsen-Friedenreich-specific monoclonal antibody. Tumor Biol.
20:139–146. 1999. View Article : Google Scholar
|
|
19
|
Karsten U, Butschak G, Cao Y, Goletz S and
Hanisch FG: A new monoclonal antibody (A78-G/A7) to the
Thomsen-Friedenreich pan-tumor antigen. Hybridoma. 14:37–44. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Topalian SL, Weiner GJ and Pardoll DM:
Cancer immunotherapy comes of age. J Clin Oncol. 29:4828–4836.
2012. View Article : Google Scholar
|
|
21
|
Xu Y, Gendler SJ and Franco A: Designer
glycopeptides for cytotoxic T cell-based elimination of carcinomas.
J Exp Med. 199:707–716. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Butschak G and Karsten U: Isolation and
characterization of thomsen-friedenreich-specific antibodies from
human serum. Tumor Biol. 23:113–122. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maloney DG: Anti-CD20 antibody therapy for
B-cell lymphomas. N Engl J Med. 366:2008–2016. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schwartz-Albiez R: Naturally occurring
antibodies directed against carbohydrate tumor antigens. Adv Exp
Med Biol. 750:27–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Glinskii OV, Sud S, Mossine VV, et al:
Inhibition of prostate cancer bone metastasis by synthetic TF
antigen mimic/galectin-3 inhibitor lactulose-L-leucine. Neoplasia.
14:65–73. 2012.PubMed/NCBI
|
